Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -44.63% is 16% below its 3-year average of -38.35%, around the middle of its 3-year range (-62.93%–-21.15%).
As of the fiscal period ended Tuesday, June 30, 2026. 10.03% above its 12-month average of -49.61%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -44.63%.
RETURN ON EQUITY (ROE)
-44.63%
RETURN ON EQUITY (ROE) AVG TTM
-49.61%
RETURN ON EQUITY (ROE) AVG 3Y
-40.78%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.03%
CURRENT VS 3Y AVG
-9.45%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.21%
median of 529 covered companies
CURRENT VS SECTOR MEDIAN
-11.00%
vs the sector median at left
ArriVent BioPharma, Inc.
Market Cap
$569.61M
Return on Equity (ROE)
-44.63%
TTM Avg
-49.61%
3Y Avg
-40.78%
5Y Avg
N/A
Market Cap
$562.50M
Return on Equity (ROE)
40.62%
TTM Avg
9.52%
3Y Avg
-25.24%
5Y Avg
-32.61%
Market Cap
$562.09M
Return on Equity (ROE)
N/A
TTM Avg
161.13%
3Y Avg
93.89%
5Y Avg
96.07%
Market Cap
$560.00M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$581.51M
Return on Equity (ROE)
-11.56%
TTM Avg
-11.05%
3Y Avg
-6.83%
5Y Avg
-8.10%
Market Cap
$554.00M
Return on Equity (ROE)
N/A
TTM Avg
44.05%
3Y Avg
44.05%
5Y Avg
44.05%
Market Cap
$550.77M
Return on Equity (ROE)
-26.37%
TTM Avg
-3503.18%
3Y Avg
-1722.33%
5Y Avg
3198.08%
Market Cap
$548.88M
Return on Equity (ROE)
-60.79%
TTM Avg
-73.94%
3Y Avg
-62.04%
5Y Avg
-71.62%
Market Cap
$545.32M
Return on Equity (ROE)
-306.61%
TTM Avg
-169.61%
3Y Avg
-163.97%
5Y Avg
-73.13%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $569.61M | -44.63% | -49.61% | -40.78% | N/A |
| CorMedix Inc. (CRMD)vs › | $562.50M | 40.62% | 9.52% | -25.24% | -32.61% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $562.09M | N/A | 161.13% | 93.89% | 96.07% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $581.51M | -11.56% | -11.05% | -6.83% | -8.10% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $554.00M | N/A | 44.05% | 44.05% | 44.05% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $550.77M | -26.37% | -3503.18% | -1722.33% | 3198.08% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $548.88M | -60.79% | -73.94% | -62.04% | -71.62% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $545.32M | -306.61% | -169.61% | -163.97% | -73.13% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $595.08M | N/A | -4.73% | 76.70% | 93.92% |
ROE
-44.6%
ROA
-41.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -44.63% |
| 2026-03-31 | -44.83% |
| 2025-12-31 | -54.13% |
| 2025-09-30 | -49.64% |
| 2025-06-30 | -54.82% |
| 2025-03-31 | -62.93% |
| 2024-12-31 | -31.24% |
| 2024-09-30 | -29.21% |
| 2024-06-30 | -25.24% |
| 2024-03-31 | -23.47% |
| 2023-12-31 | -45.83% |
| 2023-09-30 | -34.08% |
| 2023-06-30 | -30.08% |
| 2023-03-31 | -23.92% |
| 2022-12-31 | -21.15% |
